Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108117
Title:
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.
Authors:
Ghosh, Anna K; Mellor, M; Prendiville, Joseph A; Thatcher, Nick
Abstract:
Natural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.
Affiliation:
Immunology Laboratory, Paterson Institute for Cancer Research, Manchester, UK.
Citation:
Recombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies. 1990, 61 (3):471-4 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Mar-1990
URI:
http://hdl.handle.net/10541/108117
PubMed ID:
2328217
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications ; All Paterson Institute for Cancer Research

Full metadata record

DC FieldValue Language
dc.contributor.authorGhosh, Anna Ken
dc.contributor.authorMellor, Men
dc.contributor.authorPrendiville, Joseph Aen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-21T16:14:22Z-
dc.date.available2010-07-21T16:14:22Z-
dc.date.issued1990-03-
dc.identifier.citationRecombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies. 1990, 61 (3):471-4 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid2328217-
dc.identifier.urihttp://hdl.handle.net/10541/108117-
dc.description.abstractNatural killer (NK) cell activity and lymphokine activated killer (LAK) cell cytotoxicity were measured in patients receiving recombinant interleukin 2 (rIL-2) and flavone acetic acid (FAA) for treatment of progressing metastatic melanoma. NK activity was increased in 23 of 26 patients and LAK activity induced in 13 of 26 patients. However, levels of cytotoxicity in the present study were not significantly greater than a previous study using rIL-2 alone. LAK cell precursors demonstrated by in vitro incubation of pretreatment lymphocytes with IL-2 and subsequent cytotoxicity were no different in the patients compared to normal controls. Analysis of cell surface phenotypes failed to reveal any significant changes in the cell populations examined, including IL-2R and Leu 19. Although five patients had tumour response, one being complete, there was no correlation with the immunological parameters examined.en
dc.language.isoenen
dc.subject.meshAdjuvants, Immunologic-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCytotoxicity, Immunologic-
dc.subject.meshDrug Evaluation-
dc.subject.meshFemale-
dc.subject.meshFlavonoids-
dc.subject.meshHumans-
dc.subject.meshInterleukin-2-
dc.subject.meshKiller Cells, Lymphokine-Activated-
dc.subject.meshKiller Cells, Natural-
dc.subject.meshMale-
dc.subject.meshMelanoma-
dc.subject.meshRecombinant Proteins-
dc.titleRecombinant interleukin-2 (rIL-2) with flavone acetic acid (FAA) in advanced malignant melanoma: immunological studies.en
dc.typeArticleen
dc.contributor.departmentImmunology Laboratory, Paterson Institute for Cancer Research, Manchester, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.